<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PIF Portfolio &#8211; Partners Medical International</title>
	<atom:link href="https://davekuhar.github.io/partners-med-static/portfolio-type/pif-portfolio/feed" rel="self" type="application/rss+xml" />
	<link>https://davekuhar.github.io/partners-med-static/</link>
	<description></description>
	<lastBuildDate>Thu, 11 Aug 2016 18:10:00 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=5.8.1</generator>

<image>
	<url>https://davekuhar.github.io/partners-med-static/wp-content/uploads/2016/11/cropped-p-favicon-32x32.png</url>
	<title>PIF Portfolio &#8211; Partners Medical International</title>
	<link>https://davekuhar.github.io/partners-med-static/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>ImmuneXcite</title>
		<link>https://davekuhar.github.io/partners-med-static/portfolio/immunexcite</link>
		
		<dc:creator><![CDATA[Beth Mollineaux]]></dc:creator>
		<pubDate>Thu, 11 Aug 2016 15:58:45 +0000</pubDate>
				<guid isPermaLink="false">http://partnersmed.wpengine.com/?post_type=portfolio&#038;p=1960</guid>

					<description><![CDATA[<p>ImmuneXcite is a product-focused biopharmaceutical company with a novel immuno-oncology technology platform which leverages both the innate and adaptive immune responses to selectively treat a wide range of tumor types. &#160;</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/immunexcite">ImmuneXcite</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><a href="http://immunexcite.com/">ImmuneXcite</a> is a product-focused biopharmaceutical company with a novel immuno-oncology technology platform which leverages both the innate and adaptive immune responses to selectively treat a wide range of tumor types.</p>
<p>&nbsp;</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/immunexcite">ImmuneXcite</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Lyndra</title>
		<link>https://davekuhar.github.io/partners-med-static/portfolio/lyndra</link>
		
		<dc:creator><![CDATA[Beth Mollineaux]]></dc:creator>
		<pubDate>Thu, 11 Aug 2016 15:31:32 +0000</pubDate>
				<guid isPermaLink="false">http://partnersmed.wpengine.com/?post_type=portfolio&#038;p=1958</guid>

					<description><![CDATA[<p>Lyndra’s sustained release formulation technology extends oral drug delivery beyond one week. The benefits of this unique technology include improved adherence, improved pharmacokinetic profiles, convenient patient experience (particularly for populations that lack easy access to care), decreased potential for antibiotic resistance, and reduced healthcare costs.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/lyndra">Lyndra</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><a href="http://www.lyndraco.com/"><strong>Lyndra’s</strong> </a>sustained release formulation technology extends oral drug delivery beyond one week. The benefits of this unique technology include improved adherence, improved pharmacokinetic profiles, convenient patient experience (particularly for populations that lack easy access to care), decreased potential for antibiotic resistance, and reduced healthcare costs.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/lyndra">Lyndra</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>HealthCatalyst</title>
		<link>https://davekuhar.github.io/partners-med-static/portfolio/healthcatalyst</link>
		
		<dc:creator><![CDATA[Beth Mollineaux]]></dc:creator>
		<pubDate>Tue, 01 Mar 2016 20:22:38 +0000</pubDate>
				<guid isPermaLink="false">http://partnersmed.wpengine.com/?post_type=portfolio&#038;p=1832</guid>

					<description><![CDATA[<p>HealthCatalyst</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/healthcatalyst">HealthCatalyst</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><a href="http://www.healthcatalyst.com/">HealthCatalyst</a></p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/healthcatalyst">HealthCatalyst</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Provasculon</title>
		<link>https://davekuhar.github.io/partners-med-static/portfolio/provasculon</link>
		
		<dc:creator><![CDATA[ts_admin]]></dc:creator>
		<pubDate>Mon, 23 Nov 2015 09:21:23 +0000</pubDate>
				<guid isPermaLink="false">http://partnershc.wpengine.com/portfolio/provasculon</guid>

					<description><![CDATA[<p>Provasculon (acquired by Mesoblast) was formed to develop new therapeutic agents for addressing wound healing, peripheral vascular disease and myocardial infarction damage.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/provasculon">Provasculon</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Provasculon (acquired by Mesoblast) was formed to develop new therapeutic agents for addressing wound healing, peripheral vascular disease and myocardial infarction damage.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/provasculon">Provasculon</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Quartet Medicine</title>
		<link>https://davekuhar.github.io/partners-med-static/portfolio/quartet-medicine</link>
		
		<dc:creator><![CDATA[ts_admin]]></dc:creator>
		<pubDate>Mon, 23 Nov 2015 09:21:23 +0000</pubDate>
				<guid isPermaLink="false">http://partnershc.wpengine.com/portfolio/quartet-medicine</guid>

					<description><![CDATA[<p>Quartet Medicine is a biotechnology company focused on the development of novel treatments for chronic pain and inflammation.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/quartet-medicine">Quartet Medicine</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Quartet Medicine is a biotechnology company focused on the development of novel treatments for chronic pain and inflammation.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/quartet-medicine">Quartet Medicine</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>QPID</title>
		<link>https://davekuhar.github.io/partners-med-static/portfolio/qpid</link>
		
		<dc:creator><![CDATA[ts_admin]]></dc:creator>
		<pubDate>Mon, 23 Nov 2015 09:21:23 +0000</pubDate>
				<guid isPermaLink="false">http://partnershc.wpengine.com/portfolio/qpid</guid>

					<description><![CDATA[<p>QPID Health is a clinical intelligence platform designed to extract meaningful clinical information at the patient level from any electronic health record (EHR) through a unique and powerful medical concept based NLP (Natural Language Processing) search engine. The technology extracts from the EHR data repository and highlights for caregivers the most relevant clinical information at&#8230;</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/qpid">QPID</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>QPID Health is a clinical intelligence platform designed to extract meaningful clinical information at the patient level from any electronic health record (EHR) through a unique and powerful medical concept based NLP (Natural Language Processing) search engine. The technology extracts from the EHR data repository and highlights for caregivers the most relevant clinical information at the point of care for each patient encounter.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/qpid">QPID</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>RaNA</title>
		<link>https://davekuhar.github.io/partners-med-static/portfolio/rana</link>
		
		<dc:creator><![CDATA[ts_admin]]></dc:creator>
		<pubDate>Mon, 23 Nov 2015 09:21:23 +0000</pubDate>
				<guid isPermaLink="false">http://partnershc.wpengine.com/portfolio/rana</guid>

					<description><![CDATA[<p>RaNA Therapeutics is pioneering the discovery of a new class of RNA-targeted medicines that selectively activate protein expression within the body’s own cells. By targeting specific genes, RaNA’s novel drugs work epigenetically to precisely upregulate the expression of beneficial proteins in order to treat or prevent disease.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/rana">RaNA</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>RaNA Therapeutics is pioneering the discovery of a new class of RNA-targeted medicines that selectively activate protein expression within the body’s own cells. By targeting specific genes, RaNA’s novel drugs work epigenetically to precisely upregulate the expression of beneficial proteins in order to treat or prevent disease.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/rana">RaNA</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Raze Therapeutics</title>
		<link>https://davekuhar.github.io/partners-med-static/portfolio/raze-therapeutics</link>
		
		<dc:creator><![CDATA[ts_admin]]></dc:creator>
		<pubDate>Mon, 23 Nov 2015 09:21:23 +0000</pubDate>
				<guid isPermaLink="false">http://partnershc.wpengine.com/portfolio/raze-therapeutics</guid>

					<description><![CDATA[<p>Raze Therapeutics, is developing the next generation of oncology therapeutics that target metabolic pathways essential to cancer growth and survival. Using their proprietary platform, they are developing a pipeline of selective therapeutics for specific solid and hematologic cancers.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/raze-therapeutics">Raze Therapeutics</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Raze Therapeutics, is developing the next generation of oncology therapeutics that target metabolic pathways essential to cancer growth and survival. Using their proprietary platform, they are developing a pipeline of selective therapeutics for specific solid and hematologic cancers.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/raze-therapeutics">Raze Therapeutics</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Sebacia</title>
		<link>https://davekuhar.github.io/partners-med-static/portfolio/sebacia</link>
		
		<dc:creator><![CDATA[ts_admin]]></dc:creator>
		<pubDate>Mon, 23 Nov 2015 09:21:23 +0000</pubDate>
				<guid isPermaLink="false">http://partnershc.wpengine.com/portfolio/sebacia</guid>

					<description><![CDATA[<p>Sebacia is developing a safe and durable treatment for acne that utilizes a laser-activated topical agent.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/sebacia">Sebacia</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Sebacia is developing a safe and durable treatment for acne that utilizes a laser-activated topical agent.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/sebacia">Sebacia</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Spero Therapeutics</title>
		<link>https://davekuhar.github.io/partners-med-static/portfolio/spero-therapeutics</link>
		
		<dc:creator><![CDATA[ts_admin]]></dc:creator>
		<pubDate>Mon, 23 Nov 2015 09:21:23 +0000</pubDate>
				<guid isPermaLink="false">http://partnershc.wpengine.com/portfolio/spero-therapeutics</guid>

					<description><![CDATA[<p>Spero Therapeutics is a product-focused biopharmaceutical company developing a pipeline of novel treatments for bacterial infections. The company’s pipeline of anti-infective agents is one of the most unique in the industry – focused exclusively on gram-negative bacterial infections.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/spero-therapeutics">Spero Therapeutics</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Spero Therapeutics is a product-focused biopharmaceutical company developing a pipeline of novel treatments for bacterial infections. The company’s pipeline of anti-infective agents is one of the most unique in the industry – focused exclusively on gram-negative bacterial infections.</p>
<p>The post <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/portfolio/spero-therapeutics">Spero Therapeutics</a> appeared first on <a rel="nofollow" href="https://davekuhar.github.io/partners-med-static/">Partners Medical International</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
